Soligenix Achieves Important Safety Milestone in its Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

FLASH 2 Study Interim Efficacy Analysis Targeted for 1H2026 HyBryteTM (0.25%) hypericin (PRNewsfoto/SOLIGENIX, INC.) "We are pleased to have reached this important milestone, confirming the expected safety to date in the confirmatory FLASH2 study," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "As patient enrollment continues to track with our initial estimates, we anticipate providing an update, including enrollment progress and the blinded aggregate response rate, ...